Efficacy and safety of potassium-competitive acid blockers in eradicating Helicobacter pylori and treating gastro-esophageal reflux disease: A systematic review and meta-analysis.

Background: and GERD. Methods: and treating GERD, using odds ratios (OR) and 95% confidence intervals (95%CI) as the effect measures. Results: eradication, vonoprazan triple therapy showed greater efficacy overall (OR 1.94 [1.19-3.17]) and compared to lansoprazole (OR 2.84 [1.97-4.11]) and rabeprazole (OR 2.63 [1.05-6.58]), though not compared to esomeprazole (OR 1.62 [0.69-3.81]). In GERD treatment, both short-term (8 weeks) and long-term (24 weeks) vonoprazan therapies were similarly effective (OR 2.55 [1.71-3.80] and OR 2.17 [1.00-4.72], respectively) and showed particular efficacy in patients with severe (grade C/D) reflux esophagitis (OR 3.51 [1.65-7.46]). Conclusions: Vonoprazan had a superior efficacy than PPI in eradicating H. pylori and treating GERD, but not for tegoprazan. PCAB demonstrated a favorable safety profile.